Efekti sistemske aplikacije IL-33 na progresiju mišjeg melanoma
Effects of systemic IL-33 treatment on the progression of murine melanoma
Author
Jevtović, AndraMentor
Radosavljević, GordanaCommittee members
Arsenijević, NebojšaVojvodić, Danilo
Jovanović, Ivan
Metadata
Show full item recordAbstract
Melanom je jedan od najagresivnijih tumora koji karakterišu povećan
invazivni i metastatski potencijal, kao i sticanje rezistencije na terapeutike. IL-33
je član familije IL-1 koji reguliše urođeni i stečeni imunski odgovor. Uloga IL-33 u
tumoru je kompleksna i nije u potpunosti razjašnjena.
Cilj studije je da se ispitaju efekti sistemske aplikacije IL-33 na progresiju
mišjeg melanoma, kao i na modulaciju antitumorskog imunskog odgovora.
Miševima čistog soja C57BL/6 je subkutanom aplikacijom ćelija B16-F1 i
B16-F10 varijeteta mišjeg melanoma transplantiran primarni melanom, dok su im
eksperimentalne metastaze indukovane posle intravenske aplikacije ćelija. Nakon
različitih modaliteta aplikacije mišjeg rekombinantnog IL-33, ispitivan je efekat
IL-33 na rast i metastaziranje melanoma. Analiziran je uticaj IL-33 na modulaciju
imunskog odgovora u metastaskom tkivu pluća.
IL-33 suprimira rast primarnog melanoma i sa većim (B16-F10) i sa manjim
metastatskim potencijalom (B16-F1), dok s druge... strane stimuliše hematogeno
metastaziranje B16-F1 varijeteta melanoma u pluća. Prometastatska aktivnost IL-33 se
ogleda u tome što redukuje citotoksički kapacitet i favorizuje imunosupresivni
fenotip CD8+
T limfocita u metastatskom tkivu pluća. Zabeležena je povećana
akumulacija mijeloidnih supresorskih ćelija, kao i regulatornih T limfocita.
Prometastatski efekat IL-33 dodatno je potvrđen i nalazom povećane koncentracije
IL-33 u serumu obolelih od melanoma sa detektovanim regionalnim metastazama.
Dobijeni nalaz ukazuje da uprkos supresivnom delovanju na rast primarnog
melanoma, IL-33 podstiče rast hematogenih metastaza i to tako što smanjuje
efikasnost stečenog antitumorskog imunskog odgovora. Prometastatski efekat IL-33 u
mišjem melanomu dovodi u pitanje njegovu eventualnu terapijsku primenu.
Melanoma is one of the most aggressive tumors, characterized by high invasiveness,
metastatic potential and resistance to therapeutics. IL-33 is member of IL-1 cytokine family
that regulates both innate and acquired immune response. The role of IL-33 in tumor
progression is complex and not fully understood.
The aim of the study is to evaluate effects of systemic IL-33 application on murine
melanoma progression, as well as the effects of IL-33 on modulation of antitumor immune
response.
For the assessment of tumor growth, wild-type C57BL/6 mice were injected
subcutaneously with B16-F1 or B16-F10 cells, whilst for experimental metastasis assays,
malignant cells were injected intravenously. Using different modalities of IL-33 application,
effects of the mouse recombinant IL-33 on growth and melanoma metastasis were evaluated.
Effects of IL-33 on antitumor immune response in metastatic lungs were analyzed.
IL-33 restricted primary tumor growth of both high metastatic (B16-F10) and low
meta...static (B16-F1) variant, while on the opposite promoted growth of the B16-F1 melanoma
metastasis in the lungs. Prometastatic IL-33 activity is reflected in significant reduction of
CD8+
T cells cytotoxicity and promotion of CD8+
T cell immunosuppressive phenotype.
There was a significant accumulation of myeloid suppressor cells and regulatory T cells in the
metastatic lung. The significance of IL-33 for melanoma metastases was also documented in a
significantly increased level of serum IL-33 melanoma patients with regional metastases.
These findings implicate that, despite restrictive effects on primary melanoma, IL-33
promotes growth of hematogenous melanoma metastasis in mice by modulation of acquired
immune response, thus questioning its usage in therapy of human advanced melanoma.